Business
Marizyme Announces Approval for DuraGraft® in India
Marizyme Announces Approval for DuraGraft® in India.
About this update from Marizyme, Inc.
[{"type":"text","content":"\n\n\n\nMarizyme Announces Approval for DuraGraft® in India\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMarizyme Announces Approval for DuraGraft® in India\nLatest Approval Joins a Growing List of Countries for Commercial Sales in 2021\nPR Newswire\nJUPITER, Fla., Jan. 14, 2021\n\n\n\nJUPITER, Fla., Jan. 14, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft® is now registered and licensed for import into India through Marizyme's distribution partner Regency Lifesciences.\n\n \n \n \n \n \n \n\n \nIndia represents the latest market approval for DuraGraft, a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries. Currently, DuraGraft is approved in the EU and seven additional countries with more world-wide approvals pending.\nDr. Neil Campbell, Marizyme, Inc. President and CEO, said, \"We are excited to receive this approval in India and to be working with Regency Lifesciences to bring the healthcare professionals and patients of India this first in class product. India joins a growing list of countries that will form the basis of our commercial efforts in 2021 for DuraGraft.\"\nAbel Alexander, Regency Lifesciences CEO, said, \"This approval and licensure represents a significant step toward providing this novel treatment to the estimated 60,000 Coronary Artery Bypass Graft Surgeries per year.\"\nAbout CABG and DuraGraft When patients with heart disease undergo CABG surgery, free vein or arterial grafts harvested from the leg, arm or chest are frequently used to bypass occluded coronary arteries; about 90% of CABG surgeries use at least one free graft. In most cases, in the time between harvesting and bypass grafting, the free graft is stored in saline or auto...